Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Dongdong Yuan; Xiangfen Shi; Liping Guo; Gaobiao Wang; Yujie Zhao; Yuling Yang; Hanjuan Zhang; Qiong Huang; Yiqiang Yuan

doi:10.12659/MSM.923758

16 June 2020 : Clinical Research

Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Dongdong Yuan^1ABCD, Xiangfen Shi^2BCD, Liping Guo^1BF, Gaobiao Wang^1BF, Yujie Zhao^1B, Yuling Yang^1B, Hanjuan Zhang^1B, Qiong Huang^1B, Yiqiang Yuan^1AE*

DOI: 10.12659/MSM.923758

Med Sci Monit 2020; 26:e923758

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Comparison of the platelet aggregation rates of the patients with bleeding events and those without bleeding events.

	Bleeding patients (n=25)	Non-bleeding patients (n=25)	P
ACA-induced platelet aggregation (%)	13.28±8.46	24.93±9.89	<0.001
ADP-induced platelet aggregation (%)	16.17±9.74	16.88±12.69	0.829
ACA+ADP-induced platelet aggregation (%)	30.70±17.79	47.28±14.84	0.003
ACA – arachidonic acid; ADP – adenosine diphosphate.

Back to the Article

Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis

Your Privacy